David D. Chang
President and CEO, Director · Allogene Therapeutics, Inc.
- 2026
- Mar 18, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies David D. Chang files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Zachary Roberts - $104K in ALLO purchases and sales in the last 12 months
- Earl Martin Douglas - $103K in ALLO purchases and sales in the last 12 months
- Geoffrey M. Parker - $88K in ALLO purchases and sales in the last 12 months
- Benjamin Machinas Beneski - $52K in ALLO purchases and sales in the last 12 months
- Annie Yoshiyama - $29K in ALLO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is David D. Chang?
David D. Chang is a corporate insider, tracked as President and CEO, Director of Allogene Therapeutics, Inc. (ALLO). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did David D. Chang last file a Form 4?
The most recent primary Form 4 on record is dated 18 March 2026, one of 2 filings going back to 2026.
Has David D. Chang been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($289K) across all tracked filings.
